Investigational drug · Phase 3
Rilvegostomig
Also called: AZD2936
Not approved by FDA. In 25 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
25
25 still active
All registered trials
37
Any phase or sponsor naming "Rilvegostomig"
First trial start
2020
Jun 3, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rilvegostomig", any sponsor or status.
Conditions studied
As listed on its trial records.
- Biliary Tract Cancer
- Gastric Cancer
- Non-small Cell Lung Cancer
- Endometrial Cancer
- Ovarian Cancer
- Non-Small Cell Lung Cancer
- Hepatocellular Carcinoma
- Gastroesophageal Junction Adenocarcinoma
- Melanoma
- Squamous Cell Carcinoma (Skin)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Ovarian cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Oncology · Gastroenterology and liver · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Rilvegostomig" as an intervention, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07431281 · 2,130 participants (planned) · Start Feb 3, 2026 · Primary completion Aug 16, 2029
Drug: Sonesitatug vedotin; Rilvegostomig and 6 more · For: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 314 sites in all
- Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06921785 · 1,220 participants (planned) · Start May 6, 2025 · Primary completion Mar 15, 2030
Drug: Tremelimumab; Rilvegostomig and 2 more · For: Hepatocellular Carcinoma
Sites: Phoenix, Arizona; Tucson, Arizona; Los Angeles, California · 226 sites in all
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06692738 · 1,160 participants (planned) · Start Nov 18, 2024 · Primary completion Jul 1, 2030
Drug: Rilvegostomig; Pembrolizumab and 3 more · For: Non-small Cell Lung Cancer
Sites: Tucson, Arizona; Springdale, Arkansas; Anaheim, California · 333 sites in all
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06627647 · 1,160 participants (planned) · Start Nov 27, 2024 · Primary completion Nov 18, 2030
Drug: Rilvegostomig; Pembrolizumab and 3 more · For: Non-squamous Non-small Cell Lung Cancer
Sites: Mobile, Alabama; Chandler, Arizona; Phoenix, Arizona · 301 sites in all
- A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07221253 · 1,100 participants (planned) · Start Dec 4, 2025 · Primary completion Jul 31, 2029
Drug: Rilvegostomig; Durvalumab and 1 more · For: Biliary Tract Cancer
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 183 sites in all
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07720284 · 915 participants (planned) · Start Jul 16, 2026 · Primary completion Sep 11, 2030
Drug: Dato-DXd; Rilvegostomig and 4 more · For: High-risk Muscle Invasive Urothelial Carcinoma
Sites: Hot Springs, Arkansas; Little Rock, Arkansas; San Francisco, California · 160 sites in all
- A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06764875 · 840 participants (planned) · Start Mar 1, 2025 · Primary completion Apr 27, 2029
Drug: Rilvegostomig; Trastuzumab deruxtecan and 6 more · For: HER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma
Sites: Anchorage, Alaska; Phoenix, Arizona; Duarte, California · 304 sites in all
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06868277 · 830 participants (planned) · Start Apr 10, 2025 · Primary completion Jan 17, 2030
Drug: Rilvegostomig; Pembrolizumab · For: Carcinoma, Non-Small Cell Lung
Sites: La Mesa, California; Los Alamitos, California; Newark, Delaware · 304 sites in all
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06109779 · 760 participants · Start Dec 4, 2023 · Primary completion Jan 2, 2029
Drug: Rilvegostomig; Placebo and 3 more · For: Biliary Tract Cancer
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 176 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast Cancer: The I-SPY2.2 Randomized Clinical Trial.
O'Sullivan CC, Kalinsky KM, Yau C, et al. · JAMA Oncol 2026
- Retracted: Volrustomig/Rilvegostomig related "triple M"-myasthenia gravis and overlap syndrome.
Cooksley T, Keh RYS, Weaver JMJ · Postgrad Med J 2026
- Rilvegostomig for Metastatic Non-Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.
Rohrberg KS, Brandão M, Castañón Álvarez E, et al. · Clin Cancer Res 2026
- Retraction of: Volrustomig/Rilvegostomig related "triple M"-myasthenia gravis and overlap syndrome.
· Postgrad Med J 2026
- Correction: TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations.
· Front Oncol 2026
- TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations.
Newsom-Davis T, Melosky B, Heist RS, et al. · Front Oncol 2025
Also in development for Biliary Tract Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- SHR-A1904Phase 35 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Advanced Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.